Lack of safe targets and strategies to induce ferroptosis selectively in cancer cells has precluded targeting ferroptosis as an anti-cancer therapy. Published in Nature, Wu et al. and Palma et al. reveal FSP1 as a more favorable target compared to the conventionally pursued GPX4, showing that FSP1 inhibitors demonstrate a promising therapeutic window in preclinical models of lung cancer and in melanoma lymph node metastasis.
Mao et al. (Thu,) studied this question.